- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07688304
The Abuse Liability of IQOS Heated Tobacco Products Among Adults Who Smoke
Studying User Sensory Experiences and Smoking Behavior of IQOS Heated Tobacco Products to Improve Harm Reduction Among Adult Cigarette Smokers
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
PRIMARY OBJECTIVES:
I. Assess the abuse liability (appeal and sensory effects) of IQOS. II. Examine the puffing topography of IQOS.
SECONDARY OBJECTIVES:
I. Evaluate the impact of flavor on the sensory effects, appeal, and puffing topography of IQOS.
II. Evaluate the effect of perceived harm on IQOS use behavior.
EXPLORATORY OBJECTIVE:
I. Examine acute changes to pulmonary health associated with IQOS use.
OUTLINE: Participants are randomized to 1 of 2 arms.
ARM I: Participants use IQOS HeatSticks (flavor matched to their usual cigarette) as much as desired (ad lib) over 60 minutes during laboratory visit 1. At least forty-eight hours later, participants smoke their usual brand cigarette (UBC) ad lib over 60 minutes during laboratory visit 2.
ARM II: Participants smoke their UBC ad lib over 60 minutes during laboratory visit 1. At least forty-eight hours later, participants use IQOS HeatSticks (flavor matched to their usual cigarette) ad lib over 60 minutes during laboratory visit 2.
Studietyp
Inskrivning (Beräknad)
Fas
- Inte tillämpbar
Kontakter och platser
Studiekontakt
- Namn: The Ohio State University Comprehensive Cancer Center
- Telefonnummer: 800-293-5066
- E-post: OSUCCCClinicaltrials@osumc.edu
Studieorter
-
-
Ohio
-
Columbus, Ohio, Förenta staterna, 43210
- Rekrytering
- Ohio State University Comprehensive Cancer Center
-
Huvudutredare:
- Alayna P. Tackett, PhD
-
Kontakt:
- Alayna P. Tackett, PhD
- Telefonnummer: 844-744-2447
- E-post: Tackett-Lab@osumc.edu
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Beskrivning
Inclusion Criteria:
- Adults 21-65 years
- Adults who smoke (defined as ≥ 5 days weekly use of either menthol or non-menthol cigarettes over the past 3 months)
- Willing to provide informed consent and abstain from using nicotine products 12 hours before each visit
- Willing to bring UBC to each study visit
- Read, write and speak English
Exclusion Criteria:
- Current use of other non-combustible nicotine products (e.g., electronic [e]-cigarettes, HTPs; [defined as ≥ 5 days weekly use in the past 30 days])
- Planning to quit nicotine use and/or use of any smoking cessation medication in the past 30 days
- Current diagnosis of any lung diseases (e.g., asthma, cystic fibrosis, or chronic obstructive pulmonary disease)
- Self-reported unstable or significant psychiatric conditions (past/stable conditions will be allowed)
- History of cardiac event or distress within the past 3 months
- Deaf, hard of hearing, or have a severe motor disability
- Are currently pregnant, planning to become pregnant, or breastfeeding (urine pregnancy test will be completed at each visit throughout the study)
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Övrig
- Tilldelning: Randomiserad
- Interventionsmodell: Crossover tilldelning
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Övrig: Arm I (IQOS HeatSticks, Usual Brand Cigarette [UBC])
Participants use IQOS HeatSticks (flavor matched to their usual cigarette) ad lib over 60 minutes during laboratory visit 1.
At least forty-eight hours later, participants smoke their UBC ad lib over 60 minutes during laboratory visit 2.
|
Use IQOS HeatSticks (flavor matched to the participant's usual cigarette)
Smoke UBC
|
|
Övrig: Arm II (UBC, IQOS HeatSticks)
Participants smoke their UBC ad lib over 60 minutes during laboratory visit 1.
At least forty-eight hours later, participants use IQOS HeatSticks (flavor matched to their usual cigarette) ad lib over 60 minutes during laboratory visit 2.
|
Use IQOS HeatSticks (flavor matched to the participant's usual cigarette)
Smoke UBC
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Product Appeal
Tidsram: Minute 5 of product use session, Minute 35 of product use session, Minute 60 of product use session
|
Participants will complete the Appeal and Sensory Quality questionnaire.
This questionnaire will ask participants to rate each study product for appeal characteristics such as liking, willingness to use again, flavor intensity, pleasantness of taste, etc. on a scale of 0 (not at all) - 100 (extremely).
Higher scores indicate greater liking, willingness to use again, flavor intensity, etc.
|
Minute 5 of product use session, Minute 35 of product use session, Minute 60 of product use session
|
|
Product Sensory Attributes
Tidsram: Minute 5 of product use session, Minute 35 of product use session, Minute 60 of product use session
|
Participants will rate sensory attributes using the Appeal and Sensory Quality questionnaire.
This questionnaire will ask participants to rate each study product for sensory attributes such as harshness, coolness, sweetness, etc. on a scale of 0 (not at all) - 100 (extremely).
Higher scores indicate greater harshness, coolness, sweetness, etc.
|
Minute 5 of product use session, Minute 35 of product use session, Minute 60 of product use session
|
|
Economic demand breakpoint
Tidsram: Minute 60 of product use session
|
The price point at which a participant is no longer willing to pay for a stick of the study product will be determined by using a cigarette purchase task questionnaire.
|
Minute 60 of product use session
|
|
Satisfaction and psychological reward
Tidsram: Minute 5 of product use session, Minute 35 of product use session, Minute 60 of product use session
|
Satisfaction and psychological reward of study product use will be measured by the Modified Cigarette Evaluation Questionnaire (mCEQ).
The mCEQ asks questions relating to satisfaction of using the study product on a scale from 0 (Not at all) - 6 (Extremely).
|
Minute 5 of product use session, Minute 35 of product use session, Minute 60 of product use session
|
|
Abuse Liability Via Puff Topography - Total Smoking Time
Tidsram: Minute 60 of product use session
|
Will be measured with a topography device that records frequency, duration, and flow rate of cigarette puffs.
These measures are combined to inform overall cigarette puff behavior.
|
Minute 60 of product use session
|
|
Abuse Liability Via Puff Topography - Average Puff Duration
Tidsram: Minute 60 of product use session
|
Will be measured with a topography device that records frequency, duration, and flow rate of cigarette puffs.
These measures are combined to inform overall cigarette puff behavior.
|
Minute 60 of product use session
|
|
Abuse Liability Via Puff Topography - Average Flow Rate
Tidsram: Minute 60 of product use session
|
Will be measured with a topography device that records frequency, duration, and flow rate of cigarette puffs.
These measures are combined to inform overall cigarette puff behavior.
|
Minute 60 of product use session
|
|
Abuse Liability Via Puff Topography - Average Inter-Puff Interval
Tidsram: Minute 60 of product use session
|
Will be measured with a topography device that records frequency, duration, and flow rate of cigarette puffs.
These measures are combined to inform overall cigarette puff behavior.
|
Minute 60 of product use session
|
|
Abuse Liability Via Puff Topography - Average Puff Volume
Tidsram: Minute 60 of product use session
|
Will be measured with a topography device that records frequency, duration, and flow rate of cigarette puffs.
These measures are combined to inform overall cigarette puff behavior.
|
Minute 60 of product use session
|
|
Craving/withdrawal
Tidsram: Minute 0 before product use session, Minute 5 of product use session, Minute 35 of product use session, minute 60 of product use session
|
Nicotine withdrawal and craving symptoms will be measured using the Minnesota Nicotine Withdrawal Scale (MNWS)
|
Minute 0 before product use session, Minute 5 of product use session, Minute 35 of product use session, minute 60 of product use session
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Spirometry FEV1
Tidsram: Minute 0 before start of product use session and minute 60 of product use session
|
Spirometry will be used to measure forced expiratory volume (FEV1)
|
Minute 0 before start of product use session and minute 60 of product use session
|
|
Spirometry FVC
Tidsram: Minute 0 before start of product use session, Minute 60 of product use session
|
Spirometry will be used to measure forced vital capacity (FVC)
|
Minute 0 before start of product use session, Minute 60 of product use session
|
|
Spirometry FEV1/FVC
Tidsram: Minute 0 before start of product use session, Minute 60 of product use session
|
Spirometry will be used to measure FEV1/FVC
|
Minute 0 before start of product use session, Minute 60 of product use session
|
|
Used filter count
Tidsram: Minute 60 of product use session
|
Will assess the number of study product consumed
|
Minute 60 of product use session
|
|
Harm Perception
Tidsram: Minute 60 of product use session
|
A harm perception questionnaire will be used to assess the relative and absolute perceived harm of IQOS products.
|
Minute 60 of product use session
|
Samarbetspartners och utredare
Samarbetspartners
Utredare
- Huvudutredare: Alayna P Tackett, PhD, Ohio State University Comprehensive Cancer Center
Publikationer och användbara länkar
Användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Andra studie-ID-nummer
- OSU-26080
- U54CA287392 (U.S.S. NIH-anslag/kontrakt)
- NCI-2026-04495 (Registeridentifierare: CTRP (Clinical Trial Reporting Program))
- STUDY20260624 (Annan identifierare: Ohio State University Comprehensive Cancer Center)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
produkt tillverkad i och exporterad från U.S.A.
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .